Get started
Author

Damian Kusmirek

Observed institution: Molecure SA (Poland)
ORCID: 0000-0003-3020-4744
Observed ORCID: 0000-0003-3020-4744
OpenAlex ID: A5048881282
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · Molecular Cancer Therapeutics · 44
PDF
Structure-Guided Discovery of OAT-4828 as Potent, Selective, and Orally Bioavailable USP7 Inhibitor with In Vivo Antileukemic Activity
2026 · Jacek Chrzanowski, Julita Nowicka, et al. · Journal of Medicinal Chemistry · 2
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · 2
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 21 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Works count: 61
Citation count: 48
H-index: 2
I10-index: 1
Year
Topic
Type